April 09, 2025

Port Delivery System With Ranibizumab for Diabetic Eye Disease

Researchers determined that the PDS may decrease the treatment burden of frequent intravitreal injections, but further research on efficacy and safety is needed.

Conexiant

April 01, 2025

Second-Generation Anti-VEGF Agents for Neovascular AMD

Second-generation anti-VEGF agents were developed to extend durability, improve fluid reduction, and reduce the need for injections while maintaining visual outcomes and safety. Brolucizumab 6 mg (Beovu; Novartis), faricimab-svoa 6 mg (Vabysmo; Genentech), and aflibercept 8 mg (Eylea HD; Regeneron) are FDA-approved second-generation anti-VEGF agents that have reshaped the treatment landscape for nAMD.

Retinal Physician

April 01, 2025

Coding Q&A: Coding Guidelines for Wet AMD

Ensure compliance and prompt payment by using proper ICD-10-CM codes for diagnosing patients with exudative age-related macular degeneration (wet AMD). Learn the guidelines for coding specific eye conditions and disease stages.

Retinal Physician

April 01, 2025

Clinical Trial Update April 2025

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

Retinal Physician

April 01, 2025

Novel Therapeutics for Neovascular AMD

Multiple trials of molecules targeting the larger anti-VEGF family and other pathways have been initiated, which may translate into a future of durable and efficacious therapies for neovascular age-related macular degeneration.

Retinal Physician

April 01, 2025

Treating Ophthalmic Artery Stenosis in Patients With AMD

The baseline fundamentals that support a perfusion mechanism as a contributing factor to disease progression in dry AMD are consistent with observations of other end organs experiencing decreased perfusion. This treatment strategy demonstrates a very real potential to disrupt the AMD disease process. 

Retinal Physician

April 01, 2025

Detecting Diagnostic and Prognostic Biomarkers of Geographic Atrophy

This is the first in a series focusing on the diagnosis and treatment of geographic atrophy.

Optometric Management

March 31, 2025

What’s Next for Myopia Management

Consensus report provides strategies that more accurately reflect the possible severity of disease.

Conexiant

March 31, 2025

Opthea Suspends ShORe, COAST Trials

Top-line data from the phase 3 trials of sozinibercept showed that the nAMD treatment failed to meet its primary BCVA endpoints in both studies.

Conexiant